Selank and Semax: Neurotrophic Peptide Research

Selank and Semax are synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both compounds have been extensively studied for their nootropic and neuroprotective properties, representing unique approaches to modulating brain function through peptide-based interventions.

Selank: Structure and Origin

Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is based on the naturally occurring immunomodulatory peptide tuftsin (TKPR) with an additional Pro-Gly-Pro sequence that enhances metabolic stability. This design allows Selank to resist enzymatic degradation while maintaining biological activity.

Mechanisms of Action

• Modulates GABA-A receptor subunit expression in the hippocampus
• Increases BDNF (brain-derived neurotrophic factor) mRNA expression
• Influences serotonin and dopamine metabolism
• Regulates expression of genes involved in neuroplasticity
• Demonstrates immunomodulatory effects through tuftsin-like activity

Semax: Structure and Origin

Semax is a synthetic analog of the ACTH (adrenocorticotropic hormone) fragment 4-10 with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Like Selank, it incorporates a Pro-Gly-Pro C-terminal extension for enhanced stability. Semax lacks the steroidogenic activity of ACTH while retaining neurotrophic properties.

Mechanisms of Action

• Increases BDNF and NGF (nerve growth factor) expression
• Activates TrkB receptor signaling pathways
• Enhances cerebral blood flow through NO-mediated mechanisms
• Modulates dopaminergic and serotonergic neurotransmission
• Demonstrates antioxidant properties in neural tissue

Neurotrophic Factor Modulation

Both peptides significantly upregulate neurotrophic factors, particularly BDNF. This protein is critical for neuronal survival, synaptic plasticity, and cognitive function. BDNF signaling through TrkB receptors activates downstream pathways including PI3K/Akt and MAPK/ERK, which promote neuronal health and plasticity.

Research shows that Semax can increase BDNF expression by 1.5-3 fold in various brain regions, while Selank demonstrates similar neurotrophic effects with additional anxiolytic properties related to its GABAergic modulation.

Research Applications

Cognitive Function Studies

Both peptides are studied in models of learning and memory. Research demonstrates enhanced performance in spatial memory tasks, improved attention, and accelerated learning in animal models. These effects are attributed to increased neuroplasticity markers and enhanced neurotrophic signaling.

Neuroprotection Research

Semax shows protective effects in models of cerebral ischemia, reducing infarct size and improving functional outcomes. The mechanisms involve enhanced antioxidant defenses, reduced excitotoxicity, and maintained neurotrophic support during injury.

Stress and Anxiety Models

Selank demonstrates anxiolytic properties in behavioral models without the sedation or dependence associated with benzodiazepines. Research suggests this is mediated through GABAergic modulation and altered expression of genes involved in stress response.

Administration Routes

In research settings, both peptides are typically administered intranasally due to their stability and ability to cross the blood-brain barrier via the olfactory route. This delivery method achieves rapid CNS distribution while avoiding first-pass metabolism.